Harbour Investments’s Outlook Therapeutics OTLK Stock Holding History

Harbour Investments’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6K	Hold	12,304	–	–	﹤0.01%	2963
2026 Q1	$2.53K	Buy	12,304 +2,152	+21%	+$930	﹤0.01%	3837
2025 Q4	$16K	Buy	10,152 +9,331	+1,137%	+$14.9K	﹤0.01%	2520
2025 Q3	$870	Hold	821	–	–	﹤0.01%	3431
2025 Q2	$1.31K	Sell	821 -31	-4%	-$49	﹤0.01%	3228
2025 Q1	$1.04K	Buy	852 +625	+275%	+$1.1K	﹤0.01%	3233
2024 Q4	$429	Buy	227 +100	+79%	+$411	﹤0.01%	3293
2024 Q3	$678	Buy	127 +62	+95%	+$454	﹤0.01%	3161
2024 Q2	$480	Hold	65	–	–	﹤0.01%	3092
2024 Q1	$776	Hold	65	–	–	﹤0.01%	2979
2023 Q4	$512	Hold	65	–	–	﹤0.01%	2925
2023 Q3	$287	Hold	65	–	–	﹤0.01%	2862
2023 Q2	$2.26K	Hold	65	–	–	﹤0.01%	2513
2023 Q1	$1.42K	Hold	65	–	–	﹤0.01%	2627
2022 Q4	$1.4K	Hold	65	–	–	﹤0.01%	2606
2022 Q3	$1K	Hold	65	–	–	﹤0.01%	2626
2022 Q2	$1K	Buy	+65	New	+$1.87K	﹤0.01%	2626
2021 Q4	$2K	Hold	65	–	–	﹤0.01%	2420
2021 Q3	$3K	Hold	65	–	–	﹤0.01%	3209
2021 Q2	$3K	Hold	65	–	–	﹤0.01%	3265
2021 Q1	$3K	Buy	+65	New	+$2.49K	﹤0.01%	3109

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Harbour Investments's OTLK Position: Q2 2026 in Review

Harbour Investments held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 12,304 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

Harbour Investments first reported a position in OTLK in Q1 2021 and has held it in 21 quarters since. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Harbour Investments held 12,304 shares of Outlook Therapeutics worth $19.6K as of Q2 2026.
Harbour Investments left its Outlook Therapeutics share count unchanged in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2963 holding.
Harbour Investments first reported a position in Outlook Therapeutics in Q1 2021 and has held it in 21 quarters since.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.